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Abstract
Background: Vascular prevention trials typically use dichotomous event outcomes although this may be inefficient
statistically and gives no indication of event severity. We assessed whether ordinal outcomes would be more
efficient and how to best analyse them.
Methods: Chief investigators of vascular prevention randomised controlled trials that showed evidence of either
benefit or harm, or were included in a systematic review that overall showed benefit or harm, shared individual
participant data from their trials. Ordered categorical versions of vascular event outcomes (such as stroke and
myocardial infarction) were analysed using 15 statistical techniques and their results then ranked, with the result
with the smallest p-value given the smallest rank. Friedman and Duncan’s multiple range tests were performed to
assess differences between tests by comparing the average ranks for each statistical test.
Results: Data from 35 trials (254,223 participants) were shared with the collaboration. 13 trials had more than two
treatment arms, resulting in 59 comparisons. Analysis approaches (Mann Whitney U, ordinal logistic regression,
multiple regression, bootstrapping) that used ordinal outcome data had a smaller average rank and therefore
appeared to be more efficient statistically than those that analysed the original binary outcomes.
Conclusions: Ordinal vascular outcome measures appear to be more efficient statistically than binary outcomes
and provide information on the severity of event. We suggest a potential role for using ordinal outcomes in
vascular prevention trials.
Keywords: Prevention, Vascular event, Analysis, Ordinal
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: philip.bath@nottingham.ac.uk
1Stroke, Mental Health & Clinical Neurosciences, University of Nottingham,
Nottingham, UK
Full list of author information is available at the end of the article
Woodhouse et al. BMC Medical Research Methodology          (2021) 21:218 
https://doi.org/10.1186/s12874-021-01388-6
Introduction
Effective vascular event prevention lies in the manage-
ment of modifiable risk factors, and also treating the
causes of an initial event in the case of secondary pre-
vention. There are numerous prevention strategies to re-
duce the risk of cardiovascular outcome events such as
stroke, myocardial infarction (MI) and bleeding. These
strategies include reducing blood pressure [1–3] and
cholesterol [4, 5], and the use of antiplatelets [6, 7],
anticoagulation [8], surgery [9, 10], and vitamins [11, 12]
to improve outcome. Some interventions may be hazard-
ous and increase vascular risk, for example hormone re-
placement therapy (HRT) [13, 14].
Effective primary and secondary prevention results in
a lower absolute risk of vascular events. As absolute
event rates are a key component in calculating sample
sizes for binary event outcomes, lower event rates mean
larger, longer and more expensive clinical trials [15].
Further, there has been an increase in the numbers of
clinical trials being undertaken, due to new therapies be-
ing tested. This combination of more and larger clinical
trials means recruitment of the required number of par-
ticipants is a difficult and competitive process [16].
Therefore, new strategies are needed to reduce clinical
trial sample size, which will reduce costs, time to com-
pletion and number of participants exposed to risks.
One possible approach is to analyse vascular preven-
tion trials in a way which incorporates more data that
could also be considered as clinically relevant. Most vas-
cular prevention trials compare binary event rates be-
tween the treatment and control group. However,
vascular event outcomes such as stroke, myocardial in-
farction (MI) and bleeding, can be fatal or nonfatal, this
generating trichotomous outcomes (a variable with three
levels; i.e. fatal event / non-fatal event / no event). Fur-
ther, non-fatal events may have different severities, so
that further extensions to the ordinal outcome may be
included to generate four or more levels of outcomes
[17, 18]. Analysis of this type of ordered categorical
event is likely to be more efficient statistically than that
of dichotomous outcomes. This opens up the potential
for reducing trial sample size or detecting smaller but
still clinically-relevant benefits. Such structuring of vas-
cular event outcomes assumes that the ordering of
events is meaningful, i.e. fatal vascular events are consid-
ered more severe than nonfatal events. Ordered categor-
ical outcomes could also be more informative to
participants and healthcare professionals than binary
ones, [17] e.g. rather than saying that an intervention re-
duces the risk of stroke, we can say that it reduces both
stroke and the severity of stroke events.
We have previously performed an empirical analysis of
published summary data taken from the primary publi-
cations of 101 vascular prevention trials that supported
the above concepts [17]. Here, we report a prospective
study based on analysis of individual participant data.
Specifically, we compared the relative statistical efficien-
cies of ordinal versus binary outcomes as part of the
Optimising the Analysis of vascular Prevention trials
Collaboration. Although the use of statistical approaches
for ordinal data is well defined in the methodological lit-
erature, its use for designing and analysing vascular pre-
vention trials is novel. We also report on the effect of




This study followed the methodology used for the opti-
mising the analysis of acute stroke trials collaboration
[19, 20]. The protocol for this research has been pub-
lished elsewhere [21]. We sought individual participant
data from randomised controlled trials assessing the pri-
mary and secondary prevention of vascular events. Po-
tentially eligible studies were identified electronically
through search engines including the Cochrane Library
and PubMed (to the end of 2016). Further information
on the search strategy is given in Supplementary Table 1.
The use of relevant filters within these search engines
was also utilised to help narrow the search for rando-
mised controlled trials. Once trials were identified, one
author (LJW), reviewed the abstracts (and results sec-
tions if necessary) to determine if the trial was eligible.
Trials were included if they showed benefit or harm ac-
cording to the trial publication, or were included in a
meta-analysis showing benefit or harm. Trials were ex-
cluded if they were neutral (showed no significant effect
on the primary outcome) and were part of a neutral
meta-analysis. Trials were also excluded if they only col-
lected data relating to the occurrence of events and not
any information regarding the severity of the event.
Data sharing
For each eligible study, lead researchers were contacted
by an email that included the study protocol and invited
them to join the collaboration and share their data. Up
to 4 reminders were sent if the researcher did not re-
spond. In some cases, data were obtained via application
to data repositories maintained either by the trial fund-
ing body (e.g. National Institute of Neurological Disor-
ders and Stroke; National Heart, Lung and Blood
Institute) or hosting commercial trial data
(clinicalstudydatarequest.com).
Trial data
Shared data included information on participant demo-
graphics (age, sex, medical history), trial design (setting,
intervention, length of follow-up) and vascular events/
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outcomes (stroke, MI, bleeding), including information
on the severity of those events (fatal, non-fatal, severe,
mild). In trials where there were more than two treat-
ment groups (e.g. factorial trials), outcomes were ana-
lysed for each treatment comparison that had been
performed in the trial’s main publication. Data were ana-
lysed according to allocated treatment using observed
outcome data only and no imputation was performed.
Formation of outcomes
Ordered categorical outcomes were created for each
available event (stroke, MI, major adverse cardiovascular
events, bleeding; Supplementary Table 4). For example,
stroke was categorised into 3, 4, 5, 6, 8 and 9-levels de-
fined by severity.
Statistical analysis
After a review of published vascular prevention trials re-
garding methods for analysing ordinalised outcomes, fif-
teen different statistical methods were chosen for
analysing treatment effects. Methods included binary lo-
gistic regression (adjusted), Cox Proportional hazards
(adjusted and unadjusted) and Chi-Square test for the
binary outcome measures, and 2xN Chi-square test,
Cochran-Armitage trend test, ordinal logistic regression
(adjusted and unadjusted), Mann-Whitney U test, Me-
dian test, t-test, multiple linear regression (adjusted) and
bootstrapping the mean rank for the ordinal outcomes
[22–26]. The Win-ratio test, which is a method where
multiple binary outcomes, with varying levels of clinical
importance, can be analysed together to determine a
‘Win ratio’ (calculated as wins/losses), was also used for
this study [27]. An overview of the chosen methods can
be seen in Table 1. For regression-based analyses, both
unadjusted and adjusted analyses were performed; ad-
justments were made for variables common to all data
sets: age, sex and history of diabetes. No transformations
of outcome were performed for any of the analysis
methods. Analyses were carried out in SAS (version 9.3).
Comparison of statistical tests
Each trial comparator dataset was analysed using each
statistical approach; an example of the application of this
methodology can be seen in Supplementary Table 5.
The results of the tests for the ordinal outcome and the
binary counterpart were then ordered within each data-
set and given a rank (numbers 1 to 15), with the smallest
rank given to the test that produced the smallest prob-
ability value (i.e. 2-sided p-value, with the exception of
the 2xN Chi-Square) within that dataset. A 2-way ana-
lysis of variance test, ANOVA-Friedman with adjust-
ment for ties [32], was used to determine if there was a
difference between the average ranking of each test
across the datasets. If the ANOVA test was significant,
Duncan’s multiple range test [33] was then performed to
assess the ordering of tests and to assess where signifi-
cant differences between tests were present. The results
of the Duncan’s multiple range test for the 3-level exten-
sions of the MI and bleeding outcomes were then more
closely inspected. As for the stroke outcomes, the
stroke/TIA 4-level outcome was chosen for closer in-
spection, rather than the 3-level, as it contained more se-
verity information and the fact that there were more
comparator datasets available for it than for any of the
other stroke outcomes. Furthermore, for this outcome
boxplots were created to show the distributions of the p-
value rankings and the p-values themselves, respectively,
across all of the available comparator datasets, for each
analysis technique used.
Assessments of validity and reliability
A number of supplementary analyses were performed to
assess the validity and reliability of the results. Firstly,
the comparison of the statistical approaches was re-
peated within subgroups of trials that shared similar
characteristics to assess whether certain methods were
more efficient for certain types of trials. Secondly, sam-
ple sizes generated using the formulas for the ordinal/
continuous statistical tests were compared to those gen-
erated using a formula for binary proportions test to de-
termine the effect of outcome/method choice on sample
size. Thirdly, the statistical assumptions of the tests were
assessed to determine if the use of these tests in these
circumstances was appropriate.
The sensitivity, or type I error, of the two most effi-
cient statistical tests (i.e. with the smallest mean rank)
were also assessed using ordinal vascular outcomes from
10 randomly selected comparator datasets. For each of
the selected comparator datasets we created a dummy
treatment variable with a neutral treatment effect so that
any treatment difference could only occur by chance.
We then, from each of the comparator datasets, gener-
ated 1000 sample datasets, using random sampling with
replacement. Tests maintaining an acceptable proportion
of type I errors would expect to see a significant result
in around 50 of the 1000 sample data sets.
Results
Trial characteristics
Of 167 identified trials (Fig. 1), data were shared with
the collaboration for 35 trials; including 254,223 partici-
pants, Supplementary Tables 2 and 3. Reasons for not
obtaining data included inability to contact the chief in-
vestigator or other investigators (e.g. emails bounced);
chief investigators did not respond to requests for data
sharing despite multiple attempts and when emails had
not bounced; chief investigators explicitly chose not to
share their data; and trial data were not available in a
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usable format, a problem particularly for some older tri-
als. Of the included trials, 15 were primary prevention
and 20 secondary prevention (Table 2). Interventions in-
cluded anticoagulants (ACT; 8 trials), antihypertensives
(AHT; 8 trials), antiplatelets (APT; 7 trials), carotid
stenting/endarterectomy (CEA; 3 trials), glucose lower-
ing (GL; 1 trial), hormone replacement therapy (HRT; 2
trials), statins (4 trials) and vitamins (2 trials). From the
35 trials, a total of 59 comparator datasets were derived
with 13 trials having more than two comparator arms
(Fig. 1). Further information regarding the included trials
is given in Supplementary Tables 2 and 3.
Participant characteristics
Baseline characteristics of the 254,223 participants are
provided in Table 2. For secondary prevention trials, one
had information on qualifying event missing, and two
did not have time to randomisation data. The most con-
sistently collected baseline data included information on
age, sex and history of diabetes. Baseline characteristics
Table 1 Review of statistical analysis methods [22–27]
Analysis
method




Binary • No assumptions made about explanatory
variables
• Can adjust for
covariates





Binary • Proportionality of hazards over time
• Censoring of observations is unrelated to
prognosis
• Can adjust for
covariates
• If assumptions of the model not met
then subsequent analyses and risk






• Chi-Square – Total count is > 40 or total
count is 20–40 and the expected value of
each exposure-outcome category is > 5







• Similar to the Chi-square test but it takes into
account the ordering across categories







• Response is ordinal
• Proportionality of odds
• Can adjust for
covariates
• If assumptions of the model not met
then subsequent analyses and odds






• Response is ordinal / continuous
• Observations from both groups are
independent of one another
• Easy to interpret • Cannot adjust for covariates – there
are extensions of this method, which






• Considers the position of each observation
relative to the overall median.
• Easy to interpret • Cannot adjust for covariates
• Inefficient (low power) to detect





• Response is continuous
• Homogeneity of variances








• Response is continuous
• Linear relationship
• Homogeneity of variances
• No or little multicollinearity
• Can adjust for
covariates
• Assumes linear relationship







• Responses for each outcome are binary
• Accounts for clinical priorities of endpoints
• Prioritises the more
major component of
the outcome
• Useful for composite
outcomes




• Easy to interpret
• New method
• Doesn’t use the precise times from









• Cannot adjust for covariates
• Computationally intensive
• Doesn’t provide a meaningful point
estimate
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differed between intervention types, including age (statin
trials, mean 59 years, anticoagulation 69 years); female
sex (statin 16%, HRT 100%); history of diabetes (statin
7%, glucose lowering 100%); history of hypertension (sta-
tins 34%, antihypertensive 95%); and time to randomisa-
tion (for secondary prevention trials, anticoagulation 3
days, statins 507 days).
Stroke
The derived categorical stroke outcomes ranged between
3, 4, 5 and 8-levels; addition of TIA increased this to 4,
5, 6 and 9 levels (Supplementary Table 4). Comparison
of analyses for all levels of stroke outcome found that
ordinal analyses were rated higher than binary for 4 and
more levels (Table 3). For the 3-level stroke outcome re-
view, ordinal and binary analysis methods appeared to
have similar efficiency with adjusted binary logistic re-
gression being rated the most efficient analysis method.
Further, adjusted analyses were more efficient with lower
ranks then their univariable counterparts, e.g. for OLR,
CPH (Table 3). The results of performing the Duncan’s
multiple range test on the Stroke/TIA 4-level outcome
can be seen in Table 4. Ordinal analyses were rated su-
perior to binary, with the most efficient being the Mann-
Whitney U test and ordinal logistic regression (both un-
adjusted and adjusted); Table 4, Supplementary Fig. 1a.
These findings are also supported by the distribution of
the p-values from each of the tests across each of the
datasets, which can be seen in Supplementary Fig. 1b.
Myocardial infarction
Data on 3-level MI (fatal / non-fatal / none) were avail-
able for 33 trials (47 comparator datasets). Comparison
of analysis methods suggested that there was a signifi-
cant difference between the tests (p = 0.010) and that or-
dinal/continuous approaches were rated more efficient
than binary methods, with the exception of adjusted bin-
ary logistic regression (Table 3, Supplementary Table 6).
Bleeding
Bleeding data were available for 15 (43%) trials and it
was possible to create 3-level, 4-level and 5-level out-
comes (32, 26, and 13 comparator datasets respectively);
Supplementary Table 4. For each of these three bleeding
outcomes, ordinal/continuous analyses were more effi-
cient than binary methods. Adjusted multiple linear re-
gression, was the top-rated analysis in each case
(Table 3, Supplementary Table 7).
Major adverse vascular event (composite vascular event)
A composite outcome (fatal stroke or MI / non-fatal
stroke or MI / none) was derived for 33 trials; 47 com-
parator datasets. The comparison of analyses (Table 3)
suggested that there was a significant difference between
the tests (p < 0.0001). The most efficient method ap-
peared to be adjusted binary logistic regression, however
this approach did not differ significantly from the Mann-
Whitney U test and adjusted and unadjusted ordinal lo-
gistic regression suggesting that ordinal approaches were
just as efficient as binary methods.
Subgroup analysis
The results of the comparisons using the 4-level stroke/
TIA outcome, for subgroups including type of trial, and
the main intervention can be seen in Table 5 and Sup-
plementary Fig. 2; insufficient data were present for glu-
cose lowering and vitamin based trials. The differences
between the tests were significant for each of the trial
type subgroups (both p < 0.0001) and the top performing
analyses appeared to be Mann-Whitney U test, the win
ratio test, adjusted ordinal logistic regression and the
Cochran-Armitage trend test. Analysis methods also dif-
fered for interventions, including ACT, AHT, APT, CEA
and statins, with the best rated being the Mann-Whitney
Fig. 1 Flow diagram – Identification of included trials
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U test, bootstrapping, the win ratio test and adjusted or-
dinal logistic regression.
Sample size comparisons
The comparisons between sample sizes generated for
the binary stroke outcome and the 4-level stroke/TIA
outcome can be seen in Table 6. Sample size estimates
were generated for ordinal logistic regression, [34]
Mann-Whitney U test [35] and t-test [36], and com-
pared with binary comparison of proportions [37]. In 13
comparator datasets and relative to binary sample size
estimation, sample sizes were reduced by 34% for ordinal
Table 2 Characteristics of trial participants by type of intervention
Trials All ACT AHT APT CEA GL HRT Statins Vitamins P
All N = 8 N = 8 N = 7 N = 3 N = 1 N = 2 N = 4 N = 2
Primary (%) 15 4 (36.7%) 6 (40.0%) 0 1 (6.7%) 1 (6.7%) 2 (13.3%) 1 (6.7%) 0
Secondary (%) 20 4 (20.0%) 2 (10.0%) 7 (35.0%) 2 (10.0%) 0 0 3 (15.0%) 2 (10.0%)
Baseline
Number 35 254,223 54,713 81,058 39,714 5074 10,251 27,347 24,222 11,844
Age 35 65.1 (30.5) 69.0 (11.7) 64.6 (51.9) 66.0 (9.6) 66.6 (8.2) 62.8 (6.6) 63.4 (7.2) 59.3 (8.1) 63.7 (12.1) <
0.0001












































































































































































DBP 30 83.3 (12.0) 79.5 (12.8) 87.7 (11.1) 84.9 (11.7) 80.1
(10.0)
– 76.0 (9.2) 80.3 (10.4) 81.6 (12.1) <
0.0001
HR 14 73.1 (13.7) 75.1 (15.8) 77.5 (11.6) 73.2 (12.4) 73.1
(10.6)
















































ACT: anticoagulants; AHT: antihypertensives; APT: antiplatelets; CEA: carotid endarterectomy; DBP: diastolic blood pressure; GL: glucose lowering; HRT: hormone
replacement therapy; IHD: ischaemic heart disease; MI: myocardial infarction; HR: heart rate; OTR: onset to randomisation; SBP: systolic blood pressure; TIA:
transient ischaemic attack. Percentages (%) are out of the total number of participants with available data. Comparisons by Chi-Square test and ANOVA.
†Excluding HRT group. ‡Excluding GL group. ¥Excluding Statins group
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logistic regression and 82% for the Mann-Whitney-U
test and t-test.
Sensitivity analyses and statistical assumptions
The statistical assumptions for ordinal logistic regres-
sion (checked using the score test for proportional
odds) were upheld (p > 0.05) in 51/56 (91.1%) datasets
with 3-level stroke data and 30/35 (86%) datasets with
the 4-level Stroke/TIA outcome. The sensitivity
analysis assessing type I error, was performed on the
3-, 5- and 8-level stroke outcome, the 3-level MI out-
come and the 4-level bleeding outcome. This analysis
did not find any evidence of increased type I error
rate for the Mann-Whitney U test or ordinal logistic
regression (Supplementary Table 8).
Discussion
We found that it is more efficient statistically to analyse
vascular event data as several categories ordered by se-
verity rather than as dichotomous event / no event data.
The findings applied to both primary and secondary
prevention trials, and to a variety of intervention types
including blood pressure and lipid lowering, antithrom-
botics and carotid endarterectomy. Appropriate analysis
approaches included the Mann-Whitney U test, ordinal
logistic regression, bootstrapping, the Win ratio test and,
for some ordinal scales, multiple linear regression
Table 3 Rating of statistical tests
Outcome Levels† Comparator
datasets
P Rating of tests relative to each other
MWU Adj. OLR WR OLR BS Adj. MLR Adj. BLR Adj.
CPH
TT CAT CPH MT CSB CSO CSF
Stroke 3 56 < 0.0001 2 4 3 7 9 10 1 5 13 12 6 11 8 14 15
4 23 < 0.0001 2 3 1 6 10 12 4 5 11 13 7 8 9 14 15
5 16 0.0002 2 3 1 6 8 12 4 5 11 13 7 10 9 14 15
8 12 0.0115 3 2 1 7 8 10 4 5 13 14 6 9 11 12 15
Stroke/TIA 4 35 < 0.0001 1 3 5 2 4 8 10 12 7 6 11 9 13 14 15
5 17 < 0.0001 1 3 9 7 2 4 10 11 6 5 12 8 13 14 15
6 13 < 0.0001 1 2 9 3 6 4 10 11 7 8 12 5 13 14 15
9 12 < 0.0001 1 2 7 3 4 6 11 10 8 9 12 5 14 13 15
MI 3 47 0.010 1 6 12 5 2 7 8 11 4 3 10 14 13 9 15
Bleeding 3 32 < 0.0001 4 9 3 11 7 1 8 6 5 2 10 15 14 14 13
4 26 0.035 3 7 5 8 2 1 10 9 6 4 11 13 14 12 15
5 13 0.032 6 8 5 3 2 1 11 7 4 10 12 15 14 9 13
Vascular 3 47 < 0.0001 2 3 5 6 10 8 1 4 11 12 7 13 9 14 15
The numbers in bold represent the tests that are the most efficient and do not differ statistically from one another. The P-value is from the results of the
Friedman ANOVA. The order of the rating of test is based on the mean rank calculated by the Duncan’s multiple range test; the most efficient test (i.e. the test
with the smallest mean rank) is rated the best with a score of 1 and the least efficient with a score of 15
Abbreviations
Adj.: adjusted; BLR: binary logistic regression; BS: bootstrapping; CAT: Cochran-Armitage trend test; CPH: Cox proportional hazards; CSB: Chi-square binary event
outcome; CSF: Chi-square binary fatal event outcome; CSO: Chi-square ordinal event outcome; MLR: multiple linear regression; MT: median test; MWU: Mann-
Whitney U test; OLR: ordinal logistic regression; TT: t-test; Vascular: combination of stroke and MI; WR: win ratio test
†Defined in Supplementary Table 4.
Tables 4 Results from the Duncan’s test analysis of p-value
ranks for 4-level stroke/TIA based on 35 comparator datasets
(p < 0.0001)
Test Mean rank
MWU (4-level) A 4.69
OLR (4-level) A B 6.26
Adj. OLR (4-level) A B C 6.31
Bootstrapping (4-level) A B C 6.43
Win Ratio* A B C 6.69
CA Trend (4-level) A B C 6.71
t-test (4-level) B C 6.89
Adj. MLR (4-level) B C 6.91
Median test (4-level) B C D 8.06
Adj. BLR (Binary) C D E 8.49
CPH (Binary) D E 9.06
Adj. CPH (Binary) D E F 9.34
Chi-square (Binary) E F 10.37
Chi-square (4-level) F G 11.14
Chi-square (Binary fatal) G 12.66
Abbreviations
BLR: binary logistic regression; CA trend: Cochran-Armitage trend test; CPH:
Cox proportional hazards model; MLR: multiple linear regression; MWU: Mann-
Whitney U test; OLR: ordinal logistic regression
*Combined binary outcomes including (from most to least clinically
important): fatal stroke (Yes/No), Non-fatal stroke (Yes/No), and transient
ischaemic attack (Yes/No).
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(adjusted). In general, statistical regression models were
more efficient if adjusted for prognostic factors than if
performed unadjusted. Using ordinal outcome data and
efficient analyses did not carry a risk of false positive
findings. Finally, sample size estimations for ordered
outcomes were significantly lower than for dichotomous
events. These results extend our previous work based on
published trial summary data [17].
In this study, there were two methods - the Mann-
Whitney U test and win ratio test - which often ap-
peared to be more efficient than the others. Although
neither can be adjusted for covariates, extensions of
these methods do allow for covariate adjustment [28–
31]. Furthermore, though shown not to be as efficient as
the ordinal methods, there are extensions that could be
applied to the Cox proportional hazards model that
Table 5 Rating of tests by subgroups for stroke/TIA 4-level (35 comparator datasets)
Subgroup Comparator
datasets
P-value Rating of tests relative to each other
MWU Adj. OLR WR OLR BS Adj. MLR Adj. BLR Adj. CPH TT CAT CPH MT CSB CSO CSF
Trial type
Primary 15 < 0.0001 1 6 3 7 8 4 9 12 5 2 11 10 13 15 14
Secondary 20 < 0.0001 1 4 5 3 2 9 10 12 6 8 11 7 14 13 15
Main Intervention
ACT 10 0.0089 1 9 3 7 10 5 6 11 4 2 8 14 13 12 15
AHT 6 0.011 3 9 7 8 1 4 6 10 2 5 11 13 12 15 14
APT 10 < 0.0001 1 2 9 3 4 7 12 11 6 8 10 5 14 13 15
CEA 2 < 0.0001 5 3 6 4 1 7 11 14 8 9 13 2 12 10 15
HRT 2 0.35 4 2 1 5 10 3 12 6 7 8 11 9 13 15 14
Statins 4 0.0011 1 3 4 2 6 9 12 8 11 7 10 5 13 14 15
The numbers in bold represent the tests are the most efficient and do not differ statistically from one another. The P-value is from the results of the Friedman
ANOVA. The order of the rating of test is based on the mean rank calculated by the Duncan’s multiple range test; the most efficient test (i.e. the test with the
smallest mean rank) is rated the best with a score of 1 and the least efficient with a score of 15
Abbreviations
ACT: anticoagulants; Adj.: adjusted; AHT: antihypertensives; APT: antiplatelets; BLR: binary logistic regression; BS: bootstrapping; CAT: Cochran-Armitage Trend
test; CEA: carotid Endarterectomy; CPH: Cox proportional hazards; CSB: Chi-square binary event outcome; CSF: Chi-square binary fatal event outcome; CSO: Chi-
square ordinal event outcome; HRT: hormone replacement therapy; MWU: Mann-Whitney U test; MT: median test; MLR: multiple linear regression; OLR: ordinal
logistic regression; TT: t-test; Vascular: combination of stroke and MI; WR: win ratio test
Table 6 Sample size comparisons (Stroke/TIA 4-level)
Sample size Multiplier
Dataset Binary Ordinal MWU t-test Binary Ordinal MWU t-test
1 4528 4052 1194 1196 1 0.89 0.26 0.26
2 17,986 11,970 3326 3904 1 0.67 0.18 0.22
3 15,292 10,072 2744 2828 1 0.66 0.18 0.18
4 5436 2382 704 898 1 0.44 0.13 0.17
5 25,090 8666 2426 3362 1 0.35 0.097 0.13
6 30,450 10,164 2958 5070 1 0.33 0.097 0.17
13 13,510 12,610 3806 3754 1 0.93 0.28 0.28
18 23,090 22,110 6486 7194 1 0.96 0.28 0.31
30 15,934 1582 442 566 1 0.099 0.028 0.036
31 6934 1952 608 802 1 0.28 0.088 0.12
32 115,114 63,792 17,482 19,952 1 0.55 0.15 0.17
33 15,198 10,862 3388 3450 1 0.71 0.22 0.23
55 37,646 37,456 10,924 12,186 1 0.99 0.29 0.32
Median (Q1-Q3) – – – – – 0.66 (0.35–0.89) 0.18 (0.097–0.26) 0.18 (0.17–0.26)
Abbreviations
MWU: Mann-Whitney U test; Q1: lower 25% quartile; Q3: upper 75% quartile
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enable adjustment for covariates in a manner that does
not require the proportional hazards assumption for co-
variates [38].
The premise of this study is that an effective, or even
hazardous, treatment alters both the risk and severity of
an event. Although novel when considered across vascu-
lar prophylaxis, individual trials and meta-analyses have
found this before, as seen in the Heart Protection Study
with simvastatin, [39] and for HRT [40].
This study has a number of strengths. First, the study
used individual participant data, not summary data,
thereby allowing covariate adjusted analyses. Second, tri-
als included both primary and secondary prevention
studies and multiple intervention types thereby increas-
ing the external validity of the findings. Third, ordered
categorical outcomes have embedded dichotomies for
poorer versus better outcome; for example, event versus
no event, major event versus no major event and so on.
Therefore, if statistical significance is shown, further
closed testing methods can be applied to present results
for the important dichotomies; this would be particularly
useful for a trichotomous outcome for which the two
embedded dichotomies are of primary interest.
Limitations
However, there are also a number of limitations appar-
ent. First, individual data were not shared for a majority
of identified trials, a common problem in data pooling
projects. Although non-availability of data might cause a
systematic bias, the included trials involved both primary
and secondary prevention studies, and a range of differ-
ent interventions. Second, trials typically did not include
sufficient information to allow 4 or more levels of or-
dinal data to be generated for MI and bleeding; some
stroke trials allowed ordinal outcomes to be generated
up to 9 levels. In principle, MI could be further cate-
gorised with the addition of unstable angina and angina,
and MI could be divided into ST-elevation and non-ST
elevation. Third, we did not use all of the statistical ana-
lysis methods that are relevant potentially for analysing
ordered categorical data; rather we focussed on methods
that are readily available in statistical text books and
analysis software. Fourth, for the trials that had compari-
sons of two (or more) intervention groups to the same
control group, the rankings of the p-values are not inde-
pendent. However, this issue is unlikely to have had a
significant impact on the final results because the rank-
ings of methods were done within the respective com-
parisons. Fifth, the use of p-values (rather than
quantifying effects) to compare the performance of
methods and drawing conclusions is also a limitation as
evidence-based decision-making is only partly influenced
by p-values. However, this was necessary as different
tests produce different quantifying effects and p-values
offer a common currency. Furthermore, the ranking of
p-values within comparisons is likely to be very similar
to the ranking of standardized effect sizes. Last, there
are other comparison methods that could be considered
more suitable than the Freidman’s ANOVA and the
Duncan’s test, such as a more generally applicable ver-
sion of Friedman’s ANOVA test and a multivariate ex-
tension of the Wilcoxon signed ranks test [41], although
each method has its own limitations. Nevertheless, these
approaches were also utilised, for the same purpose, in
the published optimising the analysis of acute stroke tri-
als collaboration [19, 20].
Future directions
Future work could include reviewing the statistical ap-
proaches utilised here using data from the TARDIS trial,
which was the first prevention trial to use an ordinal
event outcome as the primary [42]. In this trial data on
other vascular events and their severity were also col-
lected, therefore it would be possible to review these
methods for these event outcomes. Another area to con-
sider is in the case of where the occurrence of more than
one type of event are of importance. In situations such
as these, trials tend to use a binary composite outcome
as the primary. An extension of the work undertaken
here would therefore be to ascertain if it is suitable to in-
clude severity information in the composite outcome as
well. Furthermore, there are certain statistical techniques
that can analyse the individual effects of an intervention
on multiple outcomes at once to determine a ‘global’ ef-
fect. It would therefore be of interest to determine if
these methods would be more efficient than those that
are typically used to analyse composite outcomes.
Conclusions
In summary, vascular outcomes can be ordinal variables
with ordering determined by the severity of the vascular
event. This improves statistical efficiency as well as pro-
viding additional information for participants, public and
healthcare practitioners. The approach appears to be
relevant to all tested vascular interventions and out-
comes (stroke, MI, major adverse cardiovascular events,
bleeding). Further, where applicable, adjusted analyses
add further statistical efficiency. The use of ordinal out-
comes as primary outcomes could also lead to significant
reductions in sample size. Future vascular prevention tri-
als should consider whether to use ordered categorical
outcomes and the statistical methods associated with
those. If this approach is chosen the resulting trials
could be smaller whilst retaining their original power,
and would test the effect of interventions on severity,
not just the absolute number of events. Implementation
of this approach might then lead to smaller, shorter and
less expensive vascular prophylaxis trials.
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What does this study add to the literature?
The use of ordinal vascular outcomes in prevention tri-
als would improve statistical efficiency as well as provid-
ing additional information for participants, public and
healthcare practitioners. If ordinal outcomes are used as
primary outcomes this could lead to significant reduc-
tions in sample size. Furthermore, the resulting trials
would not only be smaller but also retain their original
power, and would test the effect of the intervention on
severity, not just the number of events. Therefore, appli-
cation of this approach could lead to smaller, shorter
and less expensive vascular prophylaxis trials.
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